These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20954319)

  • 1. [Historical aspect of molecular-targeted therapy for cancer].
    Sone S; Otsuka K; Tobiume M; Tada H
    Nihon Rinsho; 2010 Oct; 68(10):1787-95. PubMed ID: 20954319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular targeted therapy for cancer].
    Sone S; Kuramoto T; Sato S; Mitsuhashi A; Kakiuchi S; Goto H; Tada H; Nishioka Y
    Nihon Rinsho; 2010 Jun; 68(6):997-1006. PubMed ID: 20535947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Personalized medicine and molecular targets of drugs].
    Nishiyama M
    Nihon Rinsho; 2010 Oct; 68(10):1917-22. PubMed ID: 20954340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of molecular targets in cancer drug development: major hurdles and future strategies.
    Hebar A; Valent P; Selzer E
    Expert Rev Clin Pharmacol; 2013 Jan; 6(1):23-34. PubMed ID: 23272790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer chemotherapy: a critical analysis of its 60 years of history.
    Galmarini D; Galmarini CM; Galmarini FC
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):181-99. PubMed ID: 22542531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular target therapy in cancer].
    Saijo N
    Nihon Rinsho; 2010 Oct; 68(10):1779-86. PubMed ID: 20954318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [50 years of hepatology - from therapeutic nihilism to targeted therapies].
    Manns MP
    Z Gastroenterol; 2013 Apr; 51(4):363-70. PubMed ID: 23585265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in cancer chemotherapy with special stress on molecular-targeted therapy.
    Saijo N
    Jpn J Clin Oncol; 2010 Sep; 40(9):855-62. PubMed ID: 20651047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure caused by molecularly targeted therapies for cancer.
    Jarkowski A; Glode AE; Spangenthal EJ; Wong MK
    Pharmacotherapy; 2011 Jan; 31(1):62-75. PubMed ID: 21182360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy.
    Kobayashi Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):157-64. PubMed ID: 21113055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Targeted biological treatment of solid tumours].
    Petruzelka L
    Vnitr Lek; 2011 Sep; 57(9):740-4. PubMed ID: 21957767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic reprogramming of the tumor.
    Ferreira LM; Hebrant A; Dumont JE
    Oncogene; 2012 Sep; 31(36):3999-4011. PubMed ID: 22231450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Front-line drug discovery system for cancer].
    Mizukami T
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving towards dose individualization of tyrosine kinase inhibitors.
    Klümpen HJ; Samer CF; Mathijssen RH; Schellens JH; Gurney H
    Cancer Treat Rev; 2011 Jun; 37(4):251-60. PubMed ID: 20833478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology.
    Ellis LM; Hicklin DJ
    Clin Cancer Res; 2009 Dec; 15(24):7471-7478. PubMed ID: 20008847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.